Hims vs Ro vs Found 2026: Which GLP-1 Provider Is Best?
Hims vs Ro vs Found compared head-to-head for GLP-1 weight loss in 2026. Pricing, medications, support, and contracts — plus how Trimi undercuts all three at $99/mo semaglutide.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. We compare competitor programs to help patients make informed weight loss decisions.
Quick links: Semaglutide treatment, Tirzepatide treatment, and Cheapest GLP-1 options.
More on GLP-1 Provider Comparisons
Hims vs Ro vs Found: The Big Three Compared
If you are comparing hims vs ro vs found for GLP-1 weight loss treatment in 2026, you are looking at the three largest telehealth platforms prescribing compounded semaglutide and tirzepatide online. All three provide legitimate, provider-supervised GLP-1 medication programs through FDA-registered 503B pharmacies. The differences between them come down to pricing, support models, platform features, and contract flexibility rather than medication quality. GLP-1 receptor agonists are injectable medications that reduce appetite and promote weight loss by mimicking the incretin hormone GLP-1, which regulates blood sugar and satiety signals in the brain. Clinical trials have demonstrated that semaglutide produces average weight loss of 14.9% of body weight (Wilding et al., NEJM, 2021), and tirzepatide produces average weight loss of 20.9% (Jastreboff et al., NEJM, 2022). These outcomes are consistent regardless of which provider prescribes the medication.
This three-way comparison examines each provider's strengths and weaknesses, then introduces Trimi as a fourth option that undercuts all three on price while maintaining the same clinical standards. We have compiled pricing, contract terms, support models, and 12-month cost projections to help you make an informed decision.
Complete 4-Way Comparison Table
The table below compares all four providers across the factors that matter most to patients choosing a GLP-1 weight loss program. Pricing reflects standard published rates as of April 2026.
| Feature | Hims | Ro | Found | Trimi |
|---|---|---|---|---|
| Semaglutide (Monthly) | $149 - $199/mo | $99 - $199/mo | $129 - $199/mo | $99/mo flat |
| Tirzepatide (Monthly) | $199 - $299/mo | $199 - $349/mo | $199 - $299/mo | $125/mo flat |
| Consultation Fee | Included | Included | Included | Free |
| Contract Required | No (most plans) | No (most plans) | Some plans | Never |
| App / Platform | Full health app | Integrated app | Coaching app | Clinical portal |
| Support Model | Provider consults | Provider + pharmacy | Coach + provider | Provider support |
| Shipping | Included | Included | Included | Free |
| Dose-Based Pricing | Yes, increases | Yes, increases | Yes, increases | No, flat rate |
| 12-Month Sema Cost | $1,788 - $2,388 | $1,188 - $2,388 | $1,548 - $2,388 | $1,188 |
| 12-Month Tirz Cost | $2,388 - $3,588 | $2,388 - $4,188 | $2,388 - $3,588 | $1,500 |
| Annual Savings vs Trimi (Sema) | $600 - $1,200 more | $0 - $1,200 more | $360 - $1,200 more | Baseline |
Key takeaway: Trimi's flat-rate pricing means your cost does not increase as your dose titrates up. With Hims, Ro, and Found, patients often start at the lower end of the price range and move toward the higher end as their dose increases — making the 12-month cost projections skew toward the upper ranges in practice.
Hims: The Streamlined Health Platform
Hims (formerly Hims & Hers) is one of the most recognizable names in consumer telehealth. Originally launched for men's health products like hair loss and erectile dysfunction treatments, the platform expanded into women's health and weight loss. Their GLP-1 program offers compounded semaglutide at $149 to $199 per month and compounded tirzepatide at $199 to $299 per month, with pricing varying by dose level and plan structure.
What Hims Does Well
Strong brand recognition and established telehealth infrastructure with millions of users across health verticals
Straightforward onboarding process — complete an intake questionnaire, consult with a provider, and receive medication within days
Unified health platform where patients using Hims for other treatments get a single dashboard experience
Consistent quality compounded medications from licensed 503B pharmacies with reliable fulfillment
No coaching upsells — the focus is on medication access and provider oversight without behavioral add-ons
Where Hims Falls Short
Higher semaglutide pricing than both Ro ($99 starting) and Trimi ($99 flat) — patients pay $50 to $100 more per month
Dose-dependent pricing means your monthly cost increases as you titrate to higher, more effective doses
Limited behavioral support compared to Found — no dedicated coaching or community features included
Brand premium embedded in pricing — the recognizable name contributes to higher costs without improving medication outcomes
Tirzepatide pricing up to $299 per month is $174 more than Trimi's $125 flat rate for the same compound
For a complete breakdown, read our Hims weight loss side effects guide. Also see our Hims vs Ro two-way comparison.
Ro: The Pharmacy-Integrated Model
Ro (Roman/Rory) operates a vertically integrated telehealth model that includes its own pharmacy fulfillment. This gives Ro direct control over the supply chain from prescription to doorstep delivery. Their GLP-1 program offers compounded semaglutide at $99 to $199 per month and compounded tirzepatide at $199 to $349 per month. Ro's lower starting price for semaglutide matches Trimi's baseline, though pricing scales upward with higher doses.
What Ro Does Well
Competitive starting price at $99 per month for semaglutide — the lowest entry point among the big three
Vertically integrated pharmacy model reduces fulfillment friction and potential supply chain disruptions
Established telehealth platform with strong clinical infrastructure and regulatory compliance track record
Simple, medication-focused approach without coaching complexity — get prescribed, get treated, get support as needed
Broad medication portfolio across health verticals demonstrates operational maturity and pharmacy competence
Where Ro Falls Short
Dose-dependent pricing means the $99 starting price can double to $199 as you titrate to therapeutic doses
Tirzepatide pricing reaches $349 per month at higher doses — $224 more per month than Trimi's flat $125
No dedicated coaching or behavioral support beyond standard provider consultations
The low advertised starting price creates expectations that may not hold as treatment progresses
12-month tirzepatide cost can reach $4,188 compared to Trimi's $1,500 — a difference of $2,688
For more on Ro's program, read our Ro weight loss side effects guide and Ro vs Found comparison.
Found: The Coaching-First Approach
Found differentiates itself through a behavioral science model that pairs GLP-1 medications with dedicated coaching, community support, and structured lifestyle interventions. Their program prices compounded semaglutide at $129 to $199 per month and compounded tirzepatide at $199 to $299 per month. Found positions the coaching element as a core value driver rather than an optional add-on.
What Found Does Well
Most comprehensive coaching model among the big three — dedicated coaches, behavioral tools, and community features included
Emphasis on sustainable behavioral change alongside pharmacological intervention for long-term success
Community features connect patients on similar journeys, providing accountability and shared experience
Personalized treatment plans that incorporate metabolic and behavioral assessments at intake
Research-backed behavioral science framework designed to build habits that persist after medication
Where Found Falls Short
Higher baseline pricing for semaglutide at $129/mo starting — $30 more than Ro or Trimi from day one
Some plan tiers require multi-month commitments, reducing the flexibility patients expect from telehealth
Coaching value depends on active engagement — patients who do not use coaching pay for services they do not use
The behavioral model adds complexity that some patients find unnecessary alongside effective GLP-1 medication
Tirzepatide at $199 to $299 per month still costs $74 to $174 more per month than Trimi's $125 flat rate
See our detailed Found weight loss side effects guide and Hims vs Found comparison for more.
Clinical Evidence: The Medication Matters More Than the Platform
Regardless of which provider you choose, the underlying medications are supported by the same robust clinical evidence. No telehealth platform can make semaglutide or tirzepatide work better than the molecule itself — what matters is that you receive the right medication, at the right dose, with appropriate medical oversight.
Semaglutide: STEP 1 Trial
The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) remains the landmark study establishing semaglutide 2.4 mg as a highly effective weight loss treatment. This 68-week, double-blind, randomized controlled trial enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity. Participants receiving semaglutide achieved a mean body weight reduction of 14.9% compared to 2.4% with placebo. Approximately one-third of participants lost 20% or more of their body weight — an outcome previously seen only with bariatric surgery. The medication that produced these results is the same semaglutide prescribed by Hims, Ro, Found, and Trimi.
Tirzepatide: SURMOUNT-1 Trial
The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) demonstrated that tirzepatide, a dual GIP/GLP-1 receptor agonist, produces even greater weight loss than semaglutide alone. In this 72-week trial involving 2,539 adults with obesity, participants receiving the highest dose of tirzepatide (15 mg) achieved a mean weight reduction of 20.9% of body weight. Over one-third of participants in the 15 mg group lost 25% or more of their body weight. These results apply identically to compounded tirzepatide from any provider, including Trimi's $125 per month program.
What This Means for Provider Choice
The clinical evidence confirms that the medication, not the platform, drives weight loss outcomes. A patient receiving compounded semaglutide from Trimi at $99 per month can expect the same pharmacological effect as a patient receiving it from Hims at $199 per month. The active ingredient, mechanism of action, and evidence base are identical. Provider choice should therefore be driven by cost, convenience, and the support model that aligns with your preferences — not by the assumption that a higher-priced platform delivers superior medication.
Who Should Choose Which Provider?
Each provider serves a different type of patient. The right choice depends on your priorities, budget, and what kind of experience you want alongside your GLP-1 medication.
Choose Hims If
You already use the Hims platform for other health products and want a unified experience. You prefer a well-known brand with straightforward medication delivery, do not need coaching, and are comfortable with pricing between $149 and $299 per month. You value brand familiarity over cost optimization.
Choose Ro If
You want the lowest possible starting price among the big three ($99/mo for semaglutide) and value a pharmacy-integrated model that controls fulfillment end to end. You are medication-focused, self-motivated, and do not need structured coaching. Be aware that pricing increases with dose titration, so long-term costs may exceed the starting rate.
Choose Found If
You believe behavioral coaching alongside medication will improve your outcomes. You want community support, structured habit-building tools, and a provider who emphasizes long-term behavioral change. You are willing to pay more for these features and will actively engage with coaching to get value from the higher price point.
Choose Trimi If
You want the most affordable access to compounded semaglutide ($99/mo) or tirzepatide ($125/mo) with flat pricing that does not increase at higher doses. You prioritize cost-effectiveness, want no contracts and no hidden fees, and understand that the medication — not the platform — drives your results. Over 12 months, you save $600 to $2,700 compared to the big three.
The Bottom Line
Hims, Ro, and Found are all legitimate GLP-1 telehealth providers with functional programs, real medical teams, and genuine medications. The differences between them are meaningful but secondary to the core fact: the same compounded semaglutide or tirzepatide is available from all three at varying price points.
Hims charges a brand premium for a streamlined experience. Ro offers competitive starting prices but scales with dose. Found provides the most coaching support but at the highest consistent price. None of the three match Trimi's flat $99 per month for semaglutide or $125 per month for tirzepatide — pricing that stays the same regardless of dose.
For most patients, the medication itself is the primary value driver. The STEP 1 and SURMOUNT-1 trials demonstrated remarkable efficacy — 14.9% and 20.9% average weight loss respectively — and those results are tied to the molecule, not the platform dispensing it. If cost is a meaningful factor in your decision, and surveys consistently show it is, Trimi delivers the same clinical intervention at a fraction of the price.
Read our complete guide to the cheapest GLP-1 injections in 2026 for a broader market view, or start your free Trimi consultation today.
Frequently Asked Questions
Which is cheapest for semaglutide — Hims, Ro, or Found?
Ro offers the lowest starting price among the big three at $99 per month for semaglutide, though pricing can increase to $199 per month at higher doses. Found starts at $129 per month and Hims at $149 per month. However, Trimi matches Ro's lowest entry at $99 per month with flat pricing that does not increase as your dose goes up, making it the most predictable and affordable long-term option.
Is the semaglutide from Hims, Ro, and Found the same?
Yes. All three platforms provide compounded semaglutide manufactured by FDA-registered 503B pharmacies. The active pharmaceutical ingredient is identical across providers. Differences between Hims, Ro, and Found are in pricing, support models, and platform features — not medication quality or efficacy.
Which provider has the best coaching — Hims, Ro, or Found?
Found offers the most comprehensive coaching model, integrating behavioral science into their treatment program with dedicated coaches, community features, and structured check-ins. Hims and Ro focus primarily on provider consultations without dedicated coaching. Whether coaching justifies the higher price depends on whether you actively engage with it — research shows medication adherence drives most outcomes.
Do Hims, Ro, and Found require contracts?
Contract requirements vary by provider and plan. Hims and Ro generally operate on month-to-month terms for most of their GLP-1 programs. Found may require multi-month commitments on certain plan tiers. Trimi operates entirely month-to-month with no contracts, no cancellation fees, and no minimum commitment.
Can I switch from Hims, Ro, or Found to Trimi?
Yes. Switching providers is straightforward because the medication type and dosing protocols are compatible. You complete a medical intake with your new provider, and your current dose carries over. Most patients switch to Trimi to reduce costs — saving $50 to $200 per month compared to Hims, Ro, or Found while receiving the same compounded medication.
Do any of these providers accept insurance for GLP-1 medications?
None of the four providers — Hims, Ro, Found, or Trimi — typically accepts insurance for compounded GLP-1 medications. All operate on a cash-pay model. This is actually an advantage for many patients, as Trimi's $99 per month is less than what most insurance copays cost for brand-name Wegovy or Zepbound, without the prior authorization delays.
What is cheaper than all three of these providers?
Trimi offers compounded semaglutide at $99 per month and compounded tirzepatide at $125 per month — matching or beating the lowest prices from Hims, Ro, and Found. Trimi includes free consultations, free shipping, and no contracts. Over 12 months, patients save $600 to $2,700 compared to the big three depending on which provider and medication they use.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed.
- Hims weight loss program and pricing.
- Ro weight loss program and pricing.
- Found weight loss program and pricing.
- FDA guidance on compounding pharmacies.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication. GLP-1 medications require a prescription and medical supervision. Individual results vary based on starting weight, adherence, and metabolic factors. Trimi is a competitor to Hims, Ro, and Found — readers should be aware of our perspective when evaluating this comparison.